Premium
Near‐Infrared Light‐Triggered Intracellular Delivery of Anticancer Drugs Using Porous Silicon Nanoparticles Conjugated with IR820 Dyes
Author(s) -
Xia Bing,
Wang Bin,
Chen Zhenyu,
Zhang Qi,
Shi Jisen
Publication year - 2016
Publication title -
advanced materials interfaces
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.671
H-Index - 65
ISSN - 2196-7350
DOI - 10.1002/admi.201500715
Subject(s) - photothermal therapy , nanocarriers , materials science , doxorubicin , biocompatibility , porous silicon , nanotechnology , photothermal effect , nanoparticle , drug delivery , conjugated system , nanocomposite , biophysics , silicon , polymer , optoelectronics , chemotherapy , medicine , surgery , metallurgy , composite material , biology
A near‐infrared (NIR) light‐triggered system based on porous silicon nanoparticles (PSiNPs) conjugated with IR820 dyes is developed for controlled release of doxorubicin hydrocloride (DOX, anticancer drug) inside cancer cells and chemo‐photothermal combination therapy in vitro. PSiNPs are chosen as nanocarriers to encapsulate IR820 and DOX molecules because of their biocompatibility, biodegradability, and a high loading capacity of effective contents (34.2% ± 6.3%, w/w). Notably, as‐prepared DOX/IR820/PSiNPs nanocomposites also have a high release percentage (98.5%) of DOX molecules triggered by NIR light in acidic environments, compared with that (17.9%) without NIR irradiation under neutral conditions. Furthermore, using localized photostimulation with a femtosecond NIR laser of two‐photo laser scanning confocal microscope, intracellular release of DOX molecules from DOX/IR820/PSiNPs nanocomposites can be dynamically observed in situ. Finally, the combination anticancer treatments of PSiNPs‐based nanocomposites are assessed in vitro, which shows a synergistic effect including chemotherapy and photothermal therapy of cancer cells. Therefore, the therapeutic approach based on PSiNPs‐based nanocarriers integrated with IR820 and DOX molecules has a great potential on NIR light‐stimulated cancer therapy.